Modelling and treating amyotrophic lateral sclerosis through induced-pluripotent stem cells technology

Area of Science:

• Neuroscience
• Stem Cell Biology
• Genetics

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting motor neurons.
• Current treatments for ALS are limited, hindering therapeutic development.
• Access to relevant cell types for research has been a significant challenge.

Purpose of the Study:

• To review the application of induced pluripotent stem cells (iPSCs) in amyotrophic lateral sclerosis (ALS) research.
• To highlight the potential of iPSCs for disease modeling, drug screening, and cell-based therapies for ALS.
• To discuss the preclinical efficacy of iPSC-based cell therapies in ALS animal models.

Main Methods:

• Derivation of iPSCs from familial and sporadic ALS patients.
• Differentiation of iPSCs into ALS-relevant cell subtypes (motor neurons, glia).
• Reproduction of ALS disease-related phenotypes in vitro using patient-derived iPSCs.
• Review of studies on iPSC-based cell therapy in ALS animal models.

Main Results:

• iPSCs provide sustainable and renewable sources of human motor neurons and glia for ALS research.
• ALS disease phenotypes can be replicated using patient-derived iPSCs, enabling disease modeling and drug screening.
• iPSC-based cell therapy has shown promising preclinical results in ALS animal models, including slowed disease progression.

Conclusions:

• Induced pluripotent stem cell technology represents a significant advancement in understanding and potentially treating ALS.
• While challenges remain, iPSCs are paving the way for novel therapeutic strategies and drug discovery platforms for ALS.
• Further long-term studies are recommended to fully assess the potential of iPSC-based cell therapies for ALS.